Amphastar P

$22.60
(as of Jul 8, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Amphastar P

Stock Price
$22.60
Ticker Symbol
AMPH
Exchange
NASDAQ

Industry Information for Amphastar P

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Company Description for Amphastar P

Country
USA
Full Time Employees
2,028

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Fundamentals for Amphastar P

Market Capitalization
$1,077,599,872
EBITDA
$248,295,008
Dividends per Share
P/E Ratio
8.28
Forward P/E Ratio
0
Earnings per Share
$2.76
Earnings per Share Estimate Next Year
Profit Margin
19.38%
Shares Outstanding
47,139,100
Percent Owned by Insiders
23.68%
Percent Owned by Institutions
72.67%
52-Week High
52-Week Low

Technical Indicators for Amphastar P

50-Day Moving Average
200-Day Moving Average
RSI
33.01
0.82

Analyst Ratings for Amphastar P

Strong Buy
2
Buy
0
Hold
4
Sell
0
Strong Sell
0

News About Amphastar P

Jul 8, 2025, 9:37 AM EST
Amphastar Pharmaceuticals (NASDAQ:AMPH) stock reached a 52-week low, trading at 22.6 USD. See more.
Jun 30, 2025, 12:35 AM EST
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. See more.
Jun 24, 2025, 12:34 AM EST
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. See more.
Jun 19, 2025, 11:35 PM EST
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. See more.